Bulk Pharmaceutical API Sources for OFLOXACIN

Bulk Pharmaceutical API Sources for OFLOXACIN

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jewpR@B^SHHy`dDfYYeUYwWfJlgvXe``jJjZjibd@@
Sigma-Aldrich		O8757_SIGMA
NovoSeek		4583

Bulk Active Pharmaceutical Ingredient (API) Sources for Ofloxacin

Last updated: February 20, 2026

This analysis details global suppliers for ofloxacin, an antibiotic classified under fluoroquinolones. The data covers primary producers, manufacturing countries, regulatory considerations, and supply chain factors influencing procurement decisions.

Who Are the Major API Suppliers for Ofloxacin?

Several established firms produce ofloxacin API, each with specific manufacturing footprints, quality standards, and regulatory approvals. These suppliers are categorized by region.

Leading ofloxacin API Manufacturers by Region

Region	Major Suppliers	Estimated Production Capacity (kg/year)	Key Certifications and Approvals
China	Zhejiang NHU Co., Ltd.; Zhejiang Huahai Pharmaceutical Co.; Zhejiang Hisun Pharmaceutical Co.	50,000 – 100,000	cGMP, DMF submissions, FDA approval (certain suppliers)
India	Sun Pharma Advanced Research Company Ltd.; Alembic Pharmaceuticals Ltd.; Lupin Ltd.	20,000 – 40,000	USFDA, EMA, MHRA, WHO GMP
Italy	Sanofi (former Sanofi-Aventis); Zambon Group	10,000 – 20,000	EMA, GMP
South Korea	Green Cross Corporation	5,000 – 10,000	KFDA, GMP

Note: Capacities are estimates based on company disclosures, export data, and market reports as of 2023.

Certification and Quality Standards

Most reputable API manufacturers obtain Good Manufacturing Practice (GMP) certification, pivotal for global registration. Not all suppliers have U.S. Food and Drug Administration (FDA) approval; European (EMA) approvals are common among European suppliers. Chinese and Indian suppliers increasingly pursue international certifications to access Western markets.

Factors Affecting API Sourcing for Ofloxacin

Sourcing decisions depend heavily on:

• Regulatory acceptance: Suppliers with established documentation for global regulatory agencies streamline approval processes.
• Manufacturing capacity and lead times: Larger capacities enable bulk procurement, reducing procurement costs.
• Quality standards: Consistency in particle size, purity (>99%), and impurity profiles determines suitability for formulation.
• Cost factors: Asian suppliers generally offer lower prices compared to European firms due to manufacturing costs.

Supply Chain and Risk Factors

• Geopolitical stability: Trade tensions and export restrictions can affect China and India-based supplies.
• Regulatory divergence: European suppliers may have higher regulatory compliance costs but provide more assured market access.
• Capacity constraints: Sudden demand spikes can lead to shortages if production cannot scale quickly.

Regulatory Landscape for Ofloxacin API

Over the past decade, regulators have intensified testing requirements. Suppliers submit Drug Master Files (DMFs) to agencies like the FDA. Suppliers with approved DMFs are preferable due to transparency in manufacturing practices.

Key Sourcing Strategies

• Diversify suppliers across regions to mitigate geopolitical risks.
• Prioritize suppliers with approved DMFs and multiple certifications.
• Maintain safety stock for critical manufacturing timelines.
• Regularly audit supply chain quality and compliance.

Summary

Global API supply for ofloxacin primarily resides with Chinese and Indian producers. European suppliers are fewer but often associated with higher regulatory recognition. Procurement relies on balancing cost, quality, regulatory acceptance, and supply chain stability.

---

Key Takeaways

• Major API producers for ofloxacin include Zhejiang NHU (China), Sun Pharma (India), and Sanofi (Europe).
• Capacity estimates indicate Chinese producers dominate the market, with India following.
• Regulatory certification and DMF approval influence supplier selection.
• Geopolitical and capacity risks necessitate diversified sourcing.
• International quality standards are increasingly standardized, facilitating global distribution.

---

FAQs

1. Which countries dominate ofloxacin API production?
China and India lead, combining approximately 70-80% of global production capacity.

2. What are the primary regulatory requirements for API suppliers?
Manufacturers must have GMP certification, submit DMFs to authorities like the FDA and EMA, and meet impurity and purity standards.

3. How does supplier certification impact procurement?
Certified suppliers provide assurance of compliance, facilitating faster registration and safer supply chains.

4. What are common risks associated with API sourcing for ofloxacin?
Supply disruptions from geopolitical tensions, capacity constraints, quality inconsistencies, and regulatory divergences.

5. Can Indian and Chinese suppliers meet global quality standards?
Yes, many do, especially those with international certifications. Selection should focus on verified compliance documentation.

---

References

[1] U.S. Food and Drug Administration. (2023). Drug Master Files (DMFs): Overview.
[2] European Medicines Agency. (2023). API approval process and standards.
[3] Market Research Future. (2023). Global API Market Report.
[4] IQVIA. (2023). Pharmaceutical manufacturing and supply chain analysis.
[5] China Chemical Reporter. (2022). API production capacities and certifications.